-

60th ASH Annual Meeting & Exposition

The premier event in malignant and non-malignant hematology. 60th ASH Meeting will be in San Diego, CA

 

Oncopeptides will present updated data from two ongoing trials, one Poster session and one Oral Session.

 

POSTER Presentation: ANCHOR
Saturday, December 1, 2018, at 06:15 pm PST
San Diego Convention Center, Hall GH
Session Name: 653. Myeloma: Therapy, Excluding Transplantation: Poster I

 

ORAL Presentation: HORIZON
Monday, December 3, 2018, at 08:15 am PST
San Diego Convention Center, Room  6F
Session Name: 653: Myeloma: Therapy, Excluding Transplantation: Antibodies and Targeted Therapies

Upcoming events

Webcast - CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU

11:00 CET

June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU.

Annual General Meeting 2022

The Annual General Meeting in Oncopeptides AB (publ) will be held on Tuesday June 28, 2022, (changed from May 19, 2022) in Stockholm, Sweden. Due to the extraordinary situation resulting from the covid-19 pandemic, Oncopeptides’ Annual General Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting with the possibility to attend in person or to be represented by a proxy will take place. Hence, the Annual General Meeting will be held without physical presence.

Silent Period

-

Silent Period

-

Silent Period

-

Year-end report 2022

08:00 CET